Titre:
  • Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial.
Auteur:Sotiriou, Christos; Venet, David; Fumagalli, Debora; Maetens, Marion M.; Rothé, Françoise; Ignatiadis, Michail; Bradbury, Andrew; Harbeck, Nadia; Gomez, H.L.; Chang, T; Coccia-Portugal, Maria; Di Cosimo, Serena; Azambuja, Evandro; de la Peña, Lorena; Nocifero, P.; Armour, A; Eidtmann, H.; Baselga, J; Piccart-Gebhart, Martine; Loi, Sherene
Informations sur la publication:18th ECCO - 40th ESMO European Cancer Congress (September 27, 2015: Vienna, Austria)
Statut de publication:Non publié, 2015-09
Sujet CREF:Cancérologie
Médecine pathologie humaine
Sciences bio-médicales et agricoles
Langue:Anglais